Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

Study:

A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

Rationale:

n/a

Purpose:

A Phase I Study of CC-5013 in combination with Doxil, Vincristine and Decadron (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Multiple Myeloma Drug: CC-5013 Phase 1

Verified by Celgene Corporation September, 2009

Sponsored by: Celgene Corporation
Information provided by: Celgene Corporation
ClinicalTrials.gov identifier: NCT00091624

Study Type: Interventional

Study Design: Allocation: Randomized, Control: Dose Comparison, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Myeloma Program
Cleveland, Ohio 44195
United States

Robert Knight, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site